Cargando…
Follow-On Indications for Orphan Drugs Related to the Inflation Reduction Act
This cohort study assesses rates at which orphan drugs approved by the US Food and Drug Administration were also approved for supplemental (follow-on) indications.
Autores principales: | Chambers, James D., Clifford, Katherine A., Enright, Daniel E., Neumann, Peter J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427936/ https://www.ncbi.nlm.nih.gov/pubmed/37581890 http://dx.doi.org/10.1001/jamanetworkopen.2023.29006 |
Ejemplares similares
-
What Is the Purpose of the Orphan Drug Act?
por: Herder, Matthew
Publicado: (2017) -
The Inflation Reduction Act: A boon for the generic and biosimilar industry
por: Niazi, Sarfaraz K.
Publicado: (2022) -
The impact of the rare disease and Orphan Drug Act in Taiwan
por: Hsiang, Ning-Chun, et al.
Publicado: (2021) -
The Inflation Reduction Act – implications for climate change, air pollution, and health
por: Rajagopalan, Sanjay, et al.
Publicado: (2023) -
President's page: The impact of the inflation reduction act on cardiovascular disease prevention
por: Gulati, Martha
Publicado: (2023)